Trial
NCT04921358
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
BeiGene
Collaborators
—
Condition
Non-Small Cell Lung Cancer (NSCLC)
Intervention
Tislelizumab
Why stopped
Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-29